*Comparative Effectiveness of Treatment Options for Plantar Heel Pain: A Systematic Review with Network Meta-Analysis*

Opeyemi O. Babatunde1, Amardeep Legha1,2, Chris Littlewood1, Linda S Chesterton1, Martin J. Thomas1,3, Hylton B. Menz1,4, Danielle A. van der Windt1.2, Edward Roddy1,3

***May 2018***

***Competing interests: None to declare***

*Author Affiliation and Address:*

*1Arthritis Research UK Primary Care Centre*

*Research Institute for Primary Care & Health Sciences, Keele University, Staffordshire, ST5 5BG, United Kingdom*

*2Centre for Prognosis Research, Research Institute for Primary Care & Health Sciences, Keele University, Staffordshire, ST5 5BG, United Kingdom*

*3Haywood Academic Rheumatology Centre, Staffordshire and Stoke-on-Trent Partnership NHS Trust, Haywood Hospital, Burslem, Staffordshire, ST6 7AG, United Kingdom*

*4School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora Victoria, Australia.*

***Corresponding Author***: Opeyemi Babatunde

Arthritis Research UK Primary Care Centre

Research Institute for Primary Care & Health Sciences, Keele University

Staffordshire, ST5 5BG

[o.babatunde@keele.ac.uk](mailto:o.babatunde@keele.ac.uk)

Tel:  01782 733927; Fax:  01782 734719

<http://www.keele.ac.uk/pchs/>

**ABSTRACT**

**Objective:** To evaluate the comparative effectiveness of current treatment options for plantar heel pain (PHP).

**Design:** Systematic review and network meta-analysis (NMA).

**Data Sources:** Medline, EMBASE, CINAHL, AMED, PEDro, Cochrane Database, Web of Science, and WHO Clinical Trials Platform were searched from their inception until January 2018.

**Study selection:** Randomised controlled trials (RCTs) of adults with PHP investigating common treatments (i.e. corticosteroid injection, nonsteroidal anti-inflammatory drugs (NSAIDs), therapeutic exercise, orthoses and/or extracorporeal shockwave therapy (ESWT)) compared with each other or a no treatment, placebo/sham control.

**Data extraction and analysis:** Data were extracted and checked for accuracy and completeness by pairs of reviewers. Primary outcomes were pain and function. Comparative treatment effects were analysed by random effects network meta-analysis in the short, medium, and long term. Relative ranking of treatments was assessed by surface under the cumulative ranking (SUCRA) probabilities (0-100 scale).

**Results:** Thirty-one RCTs (total n= 2450 patients) were included. There was no evidence of inconsistency detected between direct and indirect treatment comparisons in the networks, but sparse data led to frequently wide confidence intervals. Available evidence does not suggest that any of the commonly used treatments for the management of PHP are better than any other, although corticosteroid injections, alone or in combination with exercise, and ESWT were ranked most likely to be effective for the management of short, medium and long term pain or function; Placebo/sham/control appeared least likely to be effective; and exercise appeared to only be beneficial for long term pain or function.

**Conclusions:** Current evidence is equivocal regarding which treatment is the most effective for the management of PHP. Given limited understanding of long-term effects, there is need for large, methodologically robust multicentre RCTs investigating and directly comparing commonly used treatments for the management of PHP.

**Systematic review registration:** PROSPERO CRD42016046963.

**Highlights**

**What is already known about the management of plantar heel pain**

* Existing pairwise meta-analyses are limited to comparisons of two or three treatment options for plantar heel pain.
* Clinical decision making regarding the best treatment option is often difficult.

**What this study adds**

* For the management of plantar heel pain, available evidence does not support the superiority of any of the commonly available treatments over another.
* However, corticosteroid injections, alone or in combination with exercise, and ESWT appear more likely to be effective for relieving plantar heel pain and improving function compared to other treatments in the short, medium and long term.
* Control treatments (which include over the counter pain medications and watchful waiting, as well as placebo interventions) generally show less beneficial effects than other treatments for patients with plantar heel pain.
* The review highlights the need for large high-quality RCTs of the commonly used interventions for the management of plantar heel pain.

**INTRODUCTION**

Plantar heel pain (PHP) is the most prevalent soft tissue foot complaint, affecting 10% of adults during their lifetime1 and accounting for 25% of all foot disorders in athletes.2 Characterised by insidious onset, localised pain in the plantar heel region which may extend to the medial arch of the foot, the cause of PHP is unclear but is likely multifactorial.  Risk factors include obesity, pronated foot type, reduced ankle or first metatarsophalangeal joint range of motion, and prolonged weight-bearing.3-5 PHP reduces mobility, impairs foot and physical function and the capacity for work, all of which have a negative impact on health-related quality of life.1 6 7

In terms of primary care management, current guidance suggests a period of watchful waiting with self-management advice followed by conservative interventions if there is no improvement, including; therapist-led exercises, foot orthoses, corticosteroid injections, and extracorporeal shockwave therapy (ESWT).8-10 Although PHP is commonly thought to be a self-limiting condition, resolution of symptoms in some patients may take up to 18 months.11 Research to date suggests treatments do offer potential benefits in terms of reduced pain and improved function,1 but clinical decision-making is hampered due to a lack of robust evidence to inform the choice of treatment.

A Cochrane systematic review12 considered a range of interventions (including exercises, foot orthoses, corticosteroid injections, ESWT, laser therapy and therapeutic ultrasound) for PHP, but was not able to pool the available data, found inconclusive evidence for the effectiveness of treatments and overall, found limited evidence to inform clinical practice. Since the publication of this review, a number of additional randomised controlled trials (RCTs) have been conducted, of which the evidence has yet to be synthesised. A recent review13 of conservative treatments for PHP included many interventions (e.g., laser therapy, orthoses, pulsed radiofrequency, dry-needling) which are not commonly used for managing PHP, and analyses were limited by lack of power (2-3 studies, mostly small sample sizes) except for the ESWT vs. placebo comparison. Also, other previous systematic reviews10 12 14-16 have focussed mostly on pair-wise comparisons of two or three treatment options.

Day to day clinical decision making, however, often involves consideration of the “most effective” among available treatment options for plantar heel pain. Network meta-analysis (NMA) as a novel synthesis of evidence allows for simultaneous inferences regarding clinical effectiveness of all available treatment options, by drawing together evidence from direct and indirect comparisons of multiple treatments.17 Compared to traditional pairwise comparisons, NMA has the potential to increase the precision of the estimates of effects. Also, NMA enables a ranking of the different treatments relative to each other and aids clinical/shared decision making for clinicians and patients who may desire to know the “best treatment” on average.17

There is a need therefore, to undertake a comprehensive, up to date systematic review of the comparative effectiveness of treatment options for PHP. Using a network meta-analysis, this study aimed to evaluate and compare the most common conservative treatment options for the management of PHP.

The specific objectives of this study were to:

1. determine the comparative effectiveness of treatments for relieving pain and improving function in patients with PHP
2. identify gaps in the available evidence, as well as identify promising treatments that require investigation in future RCTs.

**METHODS**

**Protocol / protocol registration:** This review was conducted and reported in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) extension statement for systematic reviews incorporating network meta-analyses for healthcare.18An a priori protocol was established for this review and registered with the international prospective register of systematic reviews, PROSPERO number CRD42016046963 ( <http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42016046963>).

**Patient involvement:** Patient involvement was central to the development of the research question. Within an advisory workshop which included participants who currently have or have experienced PHP (n=6) and clinicians (n=12; physiotherapists and podiatrists) involved in the management of foot pain, patients discussed their experiences of PHP and their concerns about the need to determine effective treatment options for relieving symptoms and improving function (i.e. pain free walking).

**Study eligibility:** We evaluated each identified RCT against the following predetermined selection criteria:

1. *Study population*: adults, 18 years and older with PHP (including plantar fasciitis, plantar fasciopathy, plantar fasciosis) as diagnosed by clinical examination and/or diagnostic imaging.
2. *Interventions:* The review focussed on four therapeutic interventions (i.e. exercise therapy, corticosteroid injections, nonsteroidal anti-inflammatory drugs (NSAIDs), and orthoses) that are commonly used in the management of PHP in the UK19 and an additional treatment (i.e. ESWT) which is commonly reported in the literature.

Due to an envisaged lack of suitable data on dosage and procedural variations of treatment options, this systematic review and NMA focussed primarily on comparisons of the specified core therapeutic interventions (exercise therapy, corticosteroid injections, orthoses, NSAIDs, and ESWT).

1. *Comparator:* direct comparisons between any of the five core therapeutic interventions (i.e. exercise therapy, corticosteroid injections, NSAIDs, orthoses, and ESWT) or comparisons with usual care/placebo/sham for PHP in any healthcare setting (community, primary healthcare, or secondary healthcare), and without restrictions regarding duration, frequency or intensity of treatment. Studies only comparing different procedural techniques of the same intervention (e.g. focal vs radial shockwave) were excluded.
2. *Outcome measure:* the primary outcomes for this review were pain and functional disability. In order to be eligible for inclusion, assessment of pain and /or functional disability was required, studies with less than 24 hours follow up were excluded. Pain measures were placed in a hierarchy as follows: first step pain, pain in the morning, pain on activity (e.g. walking), overall pain (or other measures of pain). This hierarchy was used to analyse the most clinically relevant data when multiple pain outcomes were reported in a RCT.

**Information sources and search strategy:** A comprehensive search strategy was developed in collaboration with an information specialist, with input from clinicians and academics in the review team. Eight electronic databases (Medline, EMBASE, CINAHL, AMED, PEDro, Cochrane Database of Systematic Reviews Cochrane Controlled Clinical Trials [CENTRAL], Web of Science, and WHO International Clinical Trials Registry Platform) were searched from their inception until January 2018 (see Appendix 1 for full search strategies). No language restrictions were applied. The bibliographies of relevant review articles and selected articles were examined for additional potentially relevant trials.

**Study selection:** In pairs, reviewers (OB, AL, CL, LSC, MJT, DvdW, ER) independently evaluated the eligibility of identified trials. At each stage of titles, abstracts and full texts selection, discrepancies were resolved through discussion between pairs of reviewers or via consensus in review team meetings.

**Risk of bias assessment:** The Cochrane Collaboration’s Risk of Bias tool20 was used to assess the quality of included trials. Trials were graded (unclear, high or low risk of bias) based on: (i) sequence generation, (ii) allocation concealment, (iii) blinding of personnel, (iv) blinding of outcome assessor, (v) incomplete outcome data, (vi) selective outcome reporting, and (vii) other bias. For each study, risk of bias items was judged as unclear when there was either insufficient information to judge as (low/high risk) or there was no related information regarding the risk of bias item in the report (further details on risk of bias assessment are presented in Appendix 1).

**Data extraction:** Using a customised, pre-tested and piloted data extraction form, risk of bias and data extraction for each included trial were performed by pairs of reviewers. Differences in quality appraisal and extracted data were resolved through discussion between pairs of reviewers and where appropriate, the opinion of other members of the review team. For each included trial, details were extracted on: design, sample size, population characteristics (e.g. age, diagnosis, duration of heel pain, interventions (professional delivering intervention, dose, duration, and number of sessions), and outcome assessment (type of outcome measure, length of follow up, and outcome measurements). Studies that provided a point estimate of the outcome together with a measure of variability (e.g. a mean and standard deviation), were taken forward for analysis. Where only sample size, median, range and/or interquartile range was given, methodology from Wan et al21 was used to calculate the sample mean and standard deviation. In instances of missing or incomplete data (for example, lack of measures of variability for follow up data), additional information was requested and obtained (where possible) through contacting primary study authors.

**Data synthesis and analysis**

All analyses were performed using STATA V.15.1 (Stata Corporation, TX, USA), under a frequentist approach, with restricted maximum likelihood used to estimate parameters. Prior to analyses, extracted data were further checked independently for completion and accuracy by the study statistician while profiling a database for the analyses. Furthermore, in order to define the treatment nodes for the network; two reviewers (HBM and ER), a podiatrist and rheumatologist, independently reviewed and classified the therapeutic interventions following a consensus process. As the objective of this systematic review was to compare different treatment options, and not to investigate the influence of dosage or intensity of interventions, the specified core therapeutic interventions (exercise therapy, corticosteroid injections, orthoses, NSAIDs, and ESWT), and usual care/placebo/sham, were allocated to six distinct nodes. Furthermore, studies involving combination(s) of any of the specified core treatments were used in our analyses in addition to the six nodes as treatment nodes with combination treatments. For example, where trial arms have involved a combination of exercise therapy and a corticosteroid injection as an intervention, corticosteroid injection + exercise was classed as a distinct treatment node. Also, where RCTs included more than one arm with the same type of treatment, the data was pooled together (e.g. for a three-armed trial22 involving a prefabricated orthoses arm, and two custom orthoses arms (differentiated by a rigid and soft material), an average of the mean outcomes and standard deviations was taken from the custom orthoses arms, and a sum taken from the arm sample sizes, in order to create a single pooled orthoses arm).

In order to obtain direct treatment effect estimates (with a 95% confidence interval [CI]) for each included comparison pairwise meta-analyses were performed. Direct and indirect estimates of effects were then analysed together in a NMA.

*Network coherence (consistency and heterogeneity)*: The important assumption underlying a NMA is that of network consistency; that is, true treatment effects are on average the same, regardless of whether they are estimated from direct or indirect evidence. This was assessed in three ways: (i) using a global Wald test (with high p-values favouring consistency);23 (ii) using a node-splitting technique which judges the consistency of direct and indirect estimates separately for each treatment comparison (with high p-values favouring consistency);24 and (iii) graphically (as a crude test), by inspection of forest plots comparing direct and pooled NMA results. Furthermore, the choice of a random or fixed effects model for each analysis was based on the magnitude of τ2 (i.e. the common between-study variance across all treatment comparisons). A structured between-studies variance-covariance matrix was used, which assumes that all treatment comparisons have a common heterogeneity variance.

Primary outcomes of pain and function were classified as: (i) short term (1 to ≤ 6 weeks post treatment), (ii) medium term (6 to ≤ 12 weeks post treatment), or (iii) long term (> 12 weeks post treatment). For short and medium term outcomes, the latest outcome data within each time-category was used for analysis. For example, if a study reported 3 and 6-week pain outcomes, only the 6-week data were used. However, because the long term category has no upper bound, a different approach was taken to reduce potential heterogeneity in results; we evaluated the spread of long term outcomes and selected the most prevalent time-point, and only retained data matching this time point for analysis. A total of six NMAs were possible (pain or function outcomes analysed separately for each time-category), and a network plot was used to graphically present the direct evidence base and assess connectedness of each network.

*Assessing comparative effectiveness of treatments*: The principal summary measure used for pain and function outcomes was the standardised mean difference (SMD). SMDs are advantageous in homogenising outcomes from different scales and instruments onto a common scale. The direction of outcome scales in the raw data were reversed where appropriate (by multiplying values by -1), to ensure all outcomes were interpreted with lower values indicative of improvements in pain or functional disability. Estimates of effects (SMDs) were interpreted according to Cohen’s rule of thumb, with values of 0.2, 0.5, and 0.8 indicative of small, moderate, and large effects, respectively25. Direct pairwise (where available) and pooled NMA estimates, along with 95% CIs, are reported for all treatment comparisons. SMDs with 95% CIs that did not include the null value (of SMD=0, i.e. no difference in comparative treatment effect), were classed as statistically significant.

*Ranking of treatments*: To further assess the comparative effectiveness of treatments, the ranking probability distributions of each treatment were generated from a simulation of 1000 replications. We used mean rank, surface under cumulative ranking curve (SUCRA) values, and cumulative ranking plots. These statistics rank treatments according to their ability to generate the largest treatment effects in each simulation, and are averaged over the 1000 replications.

*Sensitivity analysis:* To assess the robustness of the findings for pain and functional outcomes, sensitivity analysis based on risk of bias was planned but not performed. This was due to most studies showing similar (unclear) risks of bias. Sensitivity analysis by the removal of studies with unclear risk led to insufficient data to support the network.

**RESULTS**

**Characteristics of included studies:** The literature search yielded 1400 unique citations, of which 263 full-text articles were selected for full review. The study flow chart is presented in Fig.1. Of the 263 full text articles, 59 met the inclusion criteria and were subjected to quality assessment and data extraction. A further 28 articles could not be included in the network meta-analysis due to: being duplicate reports of the same RCT (n=1); examining dose regimen/technique comparisons of the same intervention (n=9); examining a similar but different treatment to commonly used interventions for PHP i.e., intracorporeal pneumatic shock therapy (n=1); and data/reporting problems where authors could not be contacted or failed to respond to queries after repeated attempts over a 3 month period (n= 17). Summary of findings and the characteristics of eligible studies that could not be incorporated into the meta-analysis are presented in Appendix 2 (Tables 1 & 2).

Thirty-one RCTs involving 2450 participants across ten different (combinations of) interventions (ESWT, ESWT + exercise, ESWT + orthoses, exercise, NSAID injection + exercise, oral NSAIDs, orthoses, corticosteroid injection, corticosteroid injection + exercise, and placebo/sham) provided sufficient data for inclusion in the NMA. Table 1 (Appendix 1) presents the characteristics of the included RCTs. RCTs were published between 1999 and 2017. The maximum length of follow up ranged from 4 weeks to 104 weeks. Most RCTs were from Europe (n=8), followed by Asia (n=6) and Australia (n=5). RCTs recruited participants mostly from primary care sources and outpatient departments of hospitals and rehabilitation centres and investigated a combination of participants with duration of PHP symptoms ranging from 10 to 287 weeks.

**Risk of bias in the evidence base**

The risk of bias assessment for the 31 included trials is presented in Fig.2a and 2b. All included studies were RCTs, however a significant proportion (35%) did not adequately report how randomisation was performed. High risk of bias was considered present most frequently (in 26% of trials) in relation to lack of blinding of participants and personnel. Many of the trial outcomes were patient reported but outcome assessment procedures were reported as blinded in 45% of the trials. The reporting of most of the trials did not provide sufficient information to accurately assess concealment of treatment allocation, thus generating a large proportion of “unclear” responses (61% of trials). Overall, fourteen 22 26-38 of the 31 trials were considered to be of low quality with fewer than 50% of risk of bias items (i.e. ≤ 3/7) classed as low risk.

**Network coherence (consistency and heterogeneity)**

NMA was possible for all (six) connected networks of evidence, which investigated pain and function outcomes separately, with follow-ups at: (i) short term, (ii) medium term, and (iii) long term. There were no signs of the consistency assumption being violated for any network (where applicable; i.e. only considering closed loop networks). Firstly, the global Wald tests for inconsistency were not significant (p = 0.822, 0.971, and 0.925 for short term pain, medium term pain, and short term function, respectively). Secondly, no statistically significant difference was observed between direct and indirect estimates when assessed separately for each treatment comparison through a node-splitting technique (all p values were >0.05). Thirdly, the 95% confidence intervals of the network and pairwise meta-analysis summary results overlapped for all three closed loop networks (Fig.1S). The heterogeneity term, τ2, was ‘moderate’ to ‘large’ in magnitude (as classed by Cohen’s rule of thumb25) for all of the networks except long term function (Appendix 1, Table 2). Hence, random effects analyses were used for all but the long term function network (whereby fixed effects analyses were used). Full raw outcome data used (including outcome scales) are provided in Appendix 1, Table 3.

**Treatments for PHP: Pain outcomes**

*Evidence base*: There were 22 studies22 26-28 30 31 33 37 39-53 (21x two-arm, 1x 3-arm) in the short term pain evidence base, with a similar sized network of 23 studies27-32 34 37 39-42 44-47 49-56 (22x two-arm, 1x 3-arm) in the medium term, and a smaller network of 10 studies29 34-38 40 44 45 49 55 (all two-arm) in the long term; as presented in Fig.3. Eight different treatment nodes were used in the short term analysis, with these same treatments and the addition of a ninth (ESWT+ exercise) used in the medium term, and eight treatments in the long term. Placebo/sham-ESWT comparisons were most prevalent across all pain outcome networks (n=6 studies in short and medium term, n=4 in long term), and the number of participants ranged from 31 (NSAID injection + exercise in long term) to 574 (ESWT in medium term). Direct evidence was available for 12 out of a possible 28 pairwise comparisons in the short term, 12/36 in the medium term, and 7/28 in the long term. Outcome follow up ranged from 2-6 weeks in the short term (n=1,744 total participants used), 2-3 months in the medium term (n=2,018), and was fixed at 12 months for the long term (n=778).

*Comparative effectiveness of treatments*: Full pairwise and network analyses results for pain are presented in Table 1. Across both pairwise and network analyses, corticosteroid injection demonstrated a statistically significant larger reduction in short term pain over oral NSAIDs (SMD 2.60, 95% CI (0.81, 4.39)); and corticosteroid injection combined with exercise showed a statistically significant larger reduction in pain compared to exercise alone (SMD 1.20, 95% CI (0.14, 2.26)). Compared to other treatments, oral NSAIDs were most often associated with the least statistically significantly reductions in short term pain (by SMD 2.25, 95% CI (0.18, 4.33) compared to orthoses, and by SMD 2.61, 95% CI (0.13, 5.09) compared to corticosteroid injection combined with exercise).

Most treatments were not statistically significantly superior to one another and underlying estimates of effect presented with very wide confidence intervals. For instance, the network comparison of ESWT combined with orthoses showed a non-statistically significant reduction in medium term pain compared to ESWT in combination with exercise (SMD=2.36, 95% CI, (-2.17, 6.89)).

With the highest SUCRA values of 79.5 and 74.4, and the best mean ranks of 2.4 and 2.8, corticosteroid injection alone and in combination with exercise ranked amongst the three most effective treatments for short term pain, 82.7% and 65.7% of the time, respectively (Fig.4A, Table 2). In contrast, oral NSAIDs (which ranked amongst the three least effective treatments 97.3% of the time), exercise alone, and placebo/sham interventions demonstrated the least comparative effectiveness for pain relief in the short term. General trends from the NMA and direct comparisons for medium term pain indicated that ESWT combined with orthoses may be more effective than other treatments (highest SUCRA value of 80.3; Fig 4B, Table 2). Oral NSAIDs, exercise, and exercise combined with ESWT were least likely to have beneficial effects for the treatment of pain due to PHP in the medium term compared to other treatments. Whilst placebo and orthoses appeared least likely to be beneficial for long term pain (85.7% and 81.0% of the time ranking amongst three least effective treatments respectively; Fig 4C, Table 2), superiority of one treatment over another for the remaining six treatments was less clear, with most of these treatments having similar rankings (average SUCRA of 60.8).

**Treatments for PHP: Function outcomes**

*Evidence base*: For function outcomes, there were fewer RCTs available for analysis compared to the pain (14 studies were in the network for short term function26 30 33 37 39 41-46 48 49 52-53, 11 for medium term30 37 41 42 44-46 49 52-53 55, and 5 for long term 35 37 44 45 49 55; all two-armed), as shown in Fig.5. Similar treatment nodes were used across the networks, with the same six used in short and medium term function analyses (ESWT, ESWT + exercise, orthoses, placebo, corticosteroid injection with and without exercise), whilst the long term analysis did not contain corticosteroid without exercise. Placebo/sham-ESWT comparisons were most common in the short (n=4 studies) and long term (n=2 studies), whilst ESWT/corticosteroid injection and corticosteroid injection with exercise/exercise alone comparisons (n=3 studies) were joint most common for medium term. The number of participants ranged from 20 (exercise in long term) to 226 (ESWT in short term), and direct evidence was available for 7 out of a possible 15, 5/15, and 4/10 comparisons, in the short, medium and long term, respectively. Outcome follow up ranged from 2-6 weeks in the short term (n=868 total participants used), 2.5-3 months in the medium term (n=811), and was fixed at 12 months for the long term (n=312).

*Comparative effectiveness of treatments*: The comparative effectiveness of treatments (both pairwise and network meta-analyses) on function outcomes are presented in Table 3. As with pain outcomes, most treatments were not significantly better than one another in the short, medium and long term; confidence intervals were often wide. Placebo/sham interventions were comparatively worse at improving functional ability than other treatments; for example, network meta-analysis showed statistically significant reductions in long term functional ability (by SMD 0.93, 95% CI (0.23, 1.63) compared to corticosteroid injection, by SMD 1.09, 95% CI (0.15, 2.03) compared to exercise, and by SMD 0.95, 95% CI (0.50, 1.40) compared to ESWT).

In agreement with the analyses on pain outcome treatment effects, placebo/sham interventions ranked least likely to improve function for patients with PHP (SUCRA values: 16.9, 28.1, and 7.3, in the short, medium, and long term respectively; Fig 6 and Table 4), followed by orthoses (SUCRA: 31.8, 42.4, and 19.4, in the short, medium, and long term respectively), and exercise alone (SUCRA: 32.2, 29.9 in the short and medium term respectively). However, exercise appeared most likely to improve functional ability for long term function (SUCRA: 82.1); whilst corticosteroid with and without exercise, and ESWT consistently ranked in the top three treatments most likely to improve functional ability.

**Comparison of effectiveness of treatments across pain and function outcomes**

Corticosteroid injection with and without exercise, and ESWT interventions appear most likely to have beneficial effects for both pain and function outcomes over all time periods (Fig 7). In contrast, placebo/sham interventions appear least likely to improve either pain or function outcomes across all time periods, whilst exercise appears to have a non-beneficial effect for short and medium term, but a beneficial effect for long term pain and function.

**Summary of findings for RCTs without suitable data for NMA**

Findings from seventeen RCTs of seven different comparisons and/or treatment combinations, including ESWT vs placebo/sham (n=11), exercise vs ESWT (n=1), and custom vs prefabricated orthosis/placebo/sham (n=3), for which suitable data could not be obtained are presented in Appendix 2, Table 1. For the comparison between ESWT and placebo/sham, with an unclear to high risk of bias across trials, ESWT is reported to be significantly more effective than sham/placebo for reducing pain in two out of three trials in the short term, and four out of seven in the medium term. There was no evidence for the effect of ESWT on function in the short term but two trials reported reduction in functional disability in the medium term. However, there was uncertainty in evidence across trials and time points as shown by very large confidence intervals and inconsistency of the magnitude of effects. For both pain and function outcomes and across time points (short, medium and long-term), trials found no difference between custom and prefabricated orthoses. All other treatment comparisons/combinations contained only one trial with mostly small sample sizes.

**DISCUSSION**

Available evidence does not suggest that any of the commonly used treatments for the management of PHP are significantly better than any other, although the results of this NMA show that corticosteroid injections alone or in combination with exercise are effective treatments for reducing pain and improving function in the short term. However, the magnitude of estimate of effect varied widely across trials with large confidence intervals. Furthermore, the overall effect of corticosteroid injections on plantar heel pain is modest, and the potential for adverse effects 15 57 such as post-injection steroid-induced increase in pain, fat pad atrophy, nerve injury, and rupture of the plantar fascia require careful consideration. There was a greater amount of evidence for ESWT but we found no evidence that this treatment confers more beneficial effects (compared to the other treatments in this study) for reducing pain and improving function among patients with PHP.

In the network meta-analyses of both pain and function, placebo/sham interventions and NSAIDs were generally shown to be the least effective treatment options. Considering PHP has long been considered to be a self-limiting pain condition, our findings indicate that first line management recommendations of PHP with over the counter pain medications, NSAIDs and a watchful waiting approach may be sub-optimal. Previous literature has suggested that delaying treatment may worsen prognosis, and potentially create a need for further health care use57. The findings of this present study supports the notion that access to treatments without a period of watchful waiting may be beneficial.

As the current NMA is the first to examine the comparative effectiveness of the most common treatments for PHP, it is difficult to directly compare the findings of the present study with those of previous NMAs which examined a limited number of treatments58, or compared dosage/technique for specific treatment options59. Previous reviews collectively indicate that exercise and foot orthoses are promising interventions for short and medium-term improvements in pain and function60 61. In this review, exercise as a stand-alone treatment was not found to consistently confer beneficial effects in reducing pain and improving function for patients with PHP in the short-term, but a beneficial effect was found for long term pain and function. There is a lack of evidence regarding the most effective exercise dose or delivery method. In this systematic review, included RCTs reported varying exercise therapy protocols, dose and regime. As with the review by Almubarak & Foster60, exercise as a treatment in this review included stretching and strengthening exercise trials; treatment comparisons including exercise in combination with other treatments such as corticosteroid injection mostly had calf stretching as the ‘exercise’ component. These exercises were mostly home based (apart from the first session that may be supervised) and were not individualised or progressed. Within the networks, foot orthoses (prefabricated or custom), were not found to be effective as a stand-alone treatment for PHP, but were mostly effective in combination with ESWT. Our findings agree with those of recent systematic reviewsshowing that foot orthoses are better than sham/placebo and may be effective for reducing pain in the medium term13 61.

**Study strengths and limitations**

In this study, direct and indirect evidence has been combined in order to assess comparative effectiveness of interventions that have not yet (or only minimally) been directly compared in robust high quality trials. There was agreement between the direct and indirect evidence which achieved consistency for specified treatments, however tests for inconsistency are likely to be underpowered, due to lack of data, as evidenced by wide 95% CIs for SMDs. As an alternative to frequentist methods which was used in the current NMA, a Bayesian three-level hierarchical NMA model may be employed. This approach has been shown to increase precision of effect estimates in meta-analysis of few trials, or a large number of treatment options which can be further sub-divided62. However, this approach was deemed to be out of scope for our NMA which mainly focusses on comparisons across different treatments. Future NMAs, especially those incorporating dose comparisons and procedural variations of the same treatment options, would benefit from Bayesian analysis.

The current study is not without limitations and must be interpreted with caution. First is the inclusion of only the most common treatments as opposed to all available treatments for the management of PHP. This decision was made in order to inform choice of treatment in primary care settings where PHP patients are mostly seen, and to evaluate interventions that are widely available and accessible to patients. Furthermore, networks would likely be disconnected when including a large number of treatments evaluated in only a small number of trials. The sparsity of data did not allow for a statistical exploration of publication bias, however, we conducted a comprehensive search of published and unpublished literature as well as employed a paired screening process to ensure all available evidence was identified. However, the findings of this review are still likely to be influenced by the small number of trials (mostly with small sample sizes) available to support direct and indirect comparisons in the network. For instance, many nodes in the networks (Fig.3 and Fig.5), were connected by only a single trial and (for some treatments) with few participants.

The loss of data associated with absence of suitable data for analysis was a challenge in this review. Related first, and more importantly, to the disparate reporting of data in scientific reports in this field, a lot of data from otherwise eligible (but excluded trials) could not be analysed mostly due to lack of reporting of treatment outcomes with a mean as well as a measure of variability. Despite concerted efforts to request this additional data from trial authors, the inability of our review to incorporate such data into evidence synthesises inadvertently led to notable research waste. As a minimum, for all trials in this field, reporting an average and a measure of variability (e.g. a mean and a standard deviation) per trial arm for each follow up period should be required. Furthermore, to avoid substantial heterogeneity, data from some trials which used a very different approach to measuring outcomes could not be combined in the network. However, this problem could be overcome through the development of and adherence to an agreed standardised set of core outcomes to be used in trials in this field. In order to minimise the loss of potentially useful evidence, details of all otherwise eligible trials were extracted with a narrative summary of findings presented (Appendix 2, Table 1). Generally, the results from these trials were found to be in agreement with the evidence presented in the network meta-analysis.

**Implications for clinical practice, policy and future research**

Within the network meta-analysis, control treatments (including placebo/sham interventions, watchful waiting approach, over the counter pain medications), and NSAIDs generally showed lack of beneficial effects for patients with PHP. For primary care first-point-of-contact decision making purposes, our findings suggest that access to treatments may be beneficial for patients with PHP.

However, findings from this review must be interpreted with caution due to limitations in quality of the evidence underpinning the analyses. Of particular concern are predominantly small sample sizes, low quality reporting of aspects of study design (especially concealment of treatment allocation), and variability in outcome measures across included studies (Appendix 1, Table 3). Furthermore, this review cannot comment on evidence for comparative effectiveness of treatment options where the influence of duration of symptoms prior to treatment may be of concern. This is due to the wide variability in the range of duration of symptoms at recruitment across studies included in this review and the fact that most trials did not report data regarding the duration of symptoms per trial arm. Future research involving patients with PHP should therefore focus on the design of large trials with head to head comparisons of active treatments, long term follow-up and higher reporting standards. Furthermore, careful consideration of trials investigating the same treatment comparisons (especially for the most promising interventions in the short and long term) is an important next step. This will enable exploration of the optimal mode of delivery, dosage, and intensity of treatments required for successful management of PHP.

**CONCLUSION**

This is the first NMA to examine the comparative effectiveness of commonly used treatments for PHP and brings together available evidence in order to aid evidence-informed clinical decisions in the management of PHP. For pain and functional outcomes, most treatments were not significantly better than others in the short, medium and long term. The comparative effectiveness of commonly used treatments (i.e. exercise therapy, corticosteroid injections, orthoses, NSAIDs, and ESWT) is limited by large variation in magnitude and imprecision of effect estimates. Findings indicate the need for large, multicentre trials directly comparing commonly used treatments for the management of PHP.

**ACKNOWLEDGEMENTS**

Thanks to Dr Nadia Corp for her help with the search strategy.

**FUNDING**

AL is supported by a National Institute for Health Research (NIHR) Research Methods Fellowship. MJT has received funding through a National Institute for Health Research (NIHR) School for Primary Care Research Launching Fellowship and is currently supported by a Health Education England (HEE)/NIHR Integrated Clinical Academic Programme Clinical Lectureship (ICA-CL-2016-02-14). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR, HEE or the Department of Health and Social Care. HBM is currently a National Health and Medical Research Council of Australia Senior Research Fellow (ID: 1135995).

**Figure Legend**

**Figure 1.** Study flow chart

**Figure 2a.** Risk of bias for all individual studies (n=31) included in the analysis.

**Figure 2b.** Summary of risk of bias across all (n=31) studies included in the analysis.

(Abbreviations: + (green circle), low risk of bias; ? (amber circle), unclear risk of bias; - (red circle), high risk of bias)

**Figure 3.** Network graph of included studies for pain outcomes, with thickness of lines and size of circles proportional to number of studies and number of participants, respectively. Shown for: A) short term evidence, B) medium term evidence, and C) long term evidence.

NOTE: black text represents number of studies, and blue text number of participants   
Treatment abbreviations: ESWT=Extracorporeal shockwave therapy, ESWT+Exe= Extracorporeal shockwave therapy combined with exercise, ESWT+Orthoses= Extracorporeal shockwave therapy combined with orthoses, Exe=exercise, NSAID Inj+Exe=oral nonsteroidal anti-inflammatory drug combined with exercise, Oral NSAID=oral nonsteroidal anti-inflammatory drug, Orthoses=prefabricated or customised foot orthoses, Placebo=usual care/placebo, Steroid Inj=corticosteroid injection, and Steroid Inj+Exe=corticosteroid injection combined with exercise.

**Figure 4.** Cumulative ranking plots to show comparative effectiveness of treatments from a pain outcome network meta-analysis, for each of: A) short term outcomes, B) medium term outcomes, and C) long term outcomes. Results based on a simulation of 1000 replications.

Treatment abbreviations: ESWT=Extracorporeal shockwave therapy, ESWT+Exe= Extracorporeal shockwave therapy combined with exercise, ESWT+Orthoses= Extracorporeal shockwave therapy combined with orthoses, Exe=exercise, NSAID Inj+Exe=oral nonsteroidal anti-inflammatory drug combined with exercise, Oral NSAID=oral nonsteroidal anti-inflammatory drug, Orthoses=prefabricated or customised foot orthoses, Placebo=usual care/placebo, Steroid Inj=corticosteroid injection, and Steroid Inj+Exe=corticosteroid injection combined with exercise.

**Figure 5.** Network graph of included studies for function outcomes, with thickness of lines and size of circles proportional to number of studies and number of participants, respectively. Shown for: A) short term evidence, B) medium term evidence, and C) long term evidence.

NOTE: black text represents number of studies, and blue text number of participants   
Treatment abbreviations: ESWT=Extracorporeal shockwave therapy, Exe=exercise, Orthoses=prefabricated or customised foot orthoses, Placebo=usual care/placebo, Steroid Inj=corticosteroid injection, and Steroid Inj+Exe=corticosteroid injection combined with exercise.

**Figure 6.** Cumulative ranking plots to show comparative effectiveness of treatments from a function outcome network meta-analysis, for each of: A) short term outcomes, B) medium term outcomes, and C) long term outcomes. Results based on a simulation of 1000 replications.

Treatment abbreviations: ESWT=Extracorporeal shockwave therapy, Exe=exercise, Orthoses=prefabricated or customised foot orthoses, Placebo=usual care/placebo, Steroid Inj=corticosteroid injection, and Steroid Inj+Exe=corticosteroid injection combined with exercise.

**Figure 7.** Scatter plots to show comparative effectiveness of treatments\*, through surface under cumulative ranking curve (SUCRA) values (0-100), for pain (x-axis) and function (y-axis) outcomes. Shown separately for each of: A) short term outcomes, B) medium term outcomes, and C) long term outcomes. Note: Higher SUCRAs indicate better performing treatments.

Note: horizontal and vertical lines added at SUCRA=50 values as a crude guide to identifying comparatively better/worse performing treatments for pain/function.

Treatment abbreviations: ESWT=Extracorporeal shockwave therapy, Exe=exercise, Orthoses=prefabricated or customised foot orthoses, Placebo=usual care/placebo, Steroid Inj=corticosteroid injection, and Steroid Inj+Exe=corticosteroid injection combined with exercise.  
\* Note that SUCRA results for four treatments are completely omitted, as data was only available for pain, but not function outcomes (ESWT+Exe= Extracorporeal shockwave therapy combined with exercise, ESWT+Orthoses= Extracorporeal shockwave therapy combined with orthoses, NSAID Inj+Exe=oral nonsteroidal anti-inflammatory drug combined with exercise, and Oral NSAID=oral nonsteroidal anti-inflammatory drug).

**Figure 1S**. Forest plots showing all direct evidence available, as well as pairwise and network meta-analysis summary estimates, for each of: A) short term pain outcomes, B) medium term pain outcomes, and C) short term function outcomes\*.

Note: blue rectangles and lines represent study level SMDs and 95% CIs respectively (with size of rectangle proportional to number of participants), and green and red diamonds represent direct and pooled NMA evidence respectively.

Treatment abbreviations: ESWT=Extracorporeal shockwave therapy, ESWT+Exe= Extracorporeal shockwave therapy combined with exercise, ESWT+Orthoses= Extracorporeal shockwave therapy combined with orthoses, Exe=exercise, Oral NSAID=oral nonsteroidal anti-inflammatory drug, Orthoses=prefabricated or customised foot orthoses, Placebo=usual care/placebo, Steroid Inj=corticosteroid injection, and Steroid Inj+Exe=corticosteroid injection combined with exercise.

\* Note: data from long term pain, medium term function and long term function networks not presented, as all three of these networks were open looped, hence direct and pooled NMA evidence were not appropriate to compare.

**REFERENCES**

1. Landorf KB. Plantar heel pain and plantar fasciitis. *BMJ Clin Evid* 2015:1111.
2. Taunton JE, Ryan MB, Clement DB, McKenzie DC, Lloyd-Smith DR, Zumbo BD. A retrospective case-control analysis of 2002 running injuries. *Br J Sports Med* 2002;36(2):95-101.
3. Riddle DL, Pulisic M, Pidcoe P, Johnson RE. Risk factors for plantar fasciitis: a matched case-control study. *J Bone Joint Surg Am* 2003;85(5):872-77.
4. Rome K, Howe T, Haslock I. Risk factors associated with the development of plantar heel pain in athletes. *The Foot*;11(3):119-25. doi: 10.1054/foot.2001.0698.
5. Irving DB, Cook JL, Menz HB. Factors associated with chronic plantar heel pain: a systematic review. *J Sci Med Sport* 2006;9(1):11-22.
6. Orchard J. Plantar fasciitis. *BMJ (Clinical research ed)* 2012;345 doi: 10.1136/bmj.e6603.
7. Tong KB, Furia J. Economic burden of plantar fasciitis treatment in the United States. *Am J Orthop (Belle Mead NJ)* 2010;39(5):227-31.
8. Map of Medicine. Plantar Fasciitis 2014 [updated 2014. Available from: http://healthguides.mapofmedicine.com/choices/map/plantar\_fasciitis1.html. accessed 07/11/2017.
9. Clinical Knowledge Summaries (CKS). Plantar Fasciitis: National Institute for Health and Care Excellence; 2014 [Available from: http://cks.nice.org.uk/plantar-fasciitis. accessed 07/11/2017.
10. Lee SY, McKeon P, Hertel J. Does the use of orthoses improve self-reported pain and function measures in patients with plantar fasciitis? A meta-analysis (Structured abstract). *Phys Ther Sport* 2009;10(1):12-18.
11. Young CC, Rutherford DS, Niedfeldt MW. Treatment of plantar fasciitis. *Am Fam Physician* 2001;63(3):467-74, 77-8.
12. Crawford F, Thomson C. Interventions for treating plantar heel pain. *The Cochrane Database of Sys Rev*  2003;3(3).
13. Salvioli S, Guidi M, Marcotulli G. The effectiveness of conservative, non-pharmacological treatment for plantar heel pain: A systematic review with meta-analysis. *The Foot* 2017; 33:57-67.
14. Hawke F, Burns J, Radford JA, du Toit V. Custom-made foot orthoses for the treatment of foot pain. *Cochrane Database of Syst Rev* 2008; (3). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006801.pub2.
15. David JA, Sankarapandian V, Christopher PR, Chatterjee A, Macaden AS. Injected corticosteroids for treating plantar heel pain in adults. *Cochrane Database of Sys Rev* 2017; (6). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009348.pub2>.
16. Sweeting D, Parish B, Hooper L, Chester R. The effectiveness of manual stretching in the treatment of plantar heel pain: a systematic review. *J. Foot Ankle Res* 2011;4 doi: 10.1186/1757-1146-4-19.
17. Salanti G. Indirect and mixed‐treatment comparison, network, or multiple‐treatments meta‐analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. *Research synthesis methods* 2012;3(2):80-97.
18. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations PRISMA Extension for Network Meta-analysis. *Ann Intern Med* 2015;162(11):777-84.
19. Grieve R, Palmer S. Physiotherapy for plantar fasciitis: a UK-wide survey of current practice. *Physiotherapy* 2017;103(2):193-200. doi: https://doi.org/10.1016/j.physio.2016.02.002.
20. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. *BMJ (Clinical research ed)* 2011;343:d5928.
21. Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC medical research methodology* 2014;14(1):135.
22. Walther M, Kratschmer B, Verschl J, et al. Effect of different orthotic concepts as first line treatment of plantar fasciitis. *Foot Ankle Surg* 2013;19(2):103-7. doi: 10.1016/j.fas.2012.12.008.
23. White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta‐analysis: model estimation using multivariate meta‐regression. *Res Synth Methods* 2012;3(2):111-25.
24. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta‐analysis. *Stat Med* 2010;29(7‐8):932-44.
25. Cohen J. Statistical power analysis for the behavioral sciences. Hilsdale. *NJ: Lawrence Earlbaum Associates* 1988.
26. Hawamdeh Z, Alghwiri AA, Nassar A. The short-term effect of extracorporeal shock wave in treating plantar fasciitis: RCT. Jordan Medical Journal 2016;50(1):1-11.
27. Mardani-Kivi M, Karimi MM, Hassanzadeh Z, et al. Treatment Outcomes of Corticosteroid Injection and Extracorporeal Shock Wave Therapy as Two Primary Therapeutic Methods for Acute Plantar Fasciitis: A Prospective Randomized Clinical Trial. *J Foot Ankle Surg* 2015;54(6):1047-52. doi: 10.1053/j.jfas.2015.04.026.
28. Yan W, Sun S, Li X. [Therapeutic effect of extracorporeal shock wave combined with orthopaedic insole on plantar fasciitis]. *Zhong nan da xue xue bao Yi xue ban* 2014;39(12):1326-30. doi: 10.11817/j.issn.1672-7347.2014.12.017.
29. Grecco MV, Brech GC, Greve JM. One-year treatment follow-up of plantar fasciitis: radial shockwaves vs. conventional physiotherapy. *CLINICS* 2013;68(8):1089-95. doi: 10.6061/clinics/2013(08)05.
30. Ryan M, Hartwell J, Fraser S, Newsham-West R, Taunton J. Comparison of a physiotherapy program versus dexamethasone injections for plantar fasciopathy in prolonged standing workers: a randomized clinical trial. *Clin J Sport Med* 2014;24(3):211-7. doi: 10.1097/jsm.0000000000000021.
31. Biswas C, Pal A, Acharya A. A comparative study of efficacy of oral nonsteroidal antiinflammatory agents and locally injectable steroid for the treatment of plantar fasciitis. *Anesth Essays Res* 2011;5(2):158-61. doi: 10.4103/0259-1162.94756.
32. Yucel I, Ozturan KE, Demiraran Y, Degirmenci E, Kaynak G. Comparison of high-dose extracorporeal shockwave therapy and intralesional corticosteroid injection in the treatment of plantar fasciitis. *J Am Podiatr Med Assoc* 2010;100(2):105-10.
33. Chow IH, Cheing GL. Comparison of different energy densities of extracorporeal shock wave therapy (ESWT) for the management of chronic heel pain. *Clin Rehabil* 2007;21(2):131-41. doi: 10.1177/0269215506069244.
34. Porter MD, Shadbolt B. Intralesional corticosteroid injection versus extracorporeal shock wave therapy for plantar fasciopathy. *Clin J Sport Med* 2005;15(3):119-24.
35. Rompe JD, Decking J, Schoellner C, Nafe B. Shock wave application for chronic plantar fasciitis in running athletes. A prospective, randomized, placebo-controlled trial. *Am J Sports Med* 2003;31(2):268-75.
36. Lizis P. Comparison between Real and Placebo Extracorporeal Shockwave Therapy for the Treatment of Chronic Plantar Fasciitis Pain in the Males. *Iranian J Public Health* 2015;44(8):1150.
37. Guevara Serna JA, Acosta Moron JA. *Revista Colombiana de Ortopedia y Traumatologia* 2017 doi: <http://dx.doi.org/10.1016/j.rccot.2017.07.004>
38. Guner S, Onder H, Guner SI, Ceylan MF, Gökalp MA, Keskin S. Effectiveness of local tenoxicam versus corticosteroid injection for plantar fasciitis treatment. *Orthopedics* 2013;36(10):e1322-6. doi: 10.3928/01477447-20130920-27.
39. Buchbinder R, Ptasznik R, Gordon J, Buchanan J, Prabaharan V, Forbes A. Ultrasound-guided extracorporeal shock wave therapy for plantar fasciitis: a randomized controlled trial. *JAMA* 2002;288(11):1364-72.
40. Haake M, Buch M, Schoellner C, et al. Extracorporeal shock wave therapy for plantar fasciitis: randomised controlled multicentre trial. *BMJ (Clinical research ed)* 2003;327(7406):75. doi: 10.1136/bmj.327.7406.75.
41. McMillan AM, Landorf KB, Gilheany MF, Bird AR, Morrow AD, Menz HB. Ultrasound guided corticosteroid injection for plantar fasciitis: randomised controlled trial. *BMJ* 2012; 344 :e3260. doi: 10.1136/bmj.e3260.
42. Oliveira HA, Jones A, Moreira E, Jennings F, Natour J. Effectiveness of total contact insoles in patients with plantar fasciitis. *J Rheumatology* 2015;42(5):870-8. doi: 10.3899/jrheum.140429.
43. Radford JA, Landorf KB, Buchbinder R, Cook C. Effectiveness of calf muscle stretching for the short-term treatment of plantar heel pain: a randomised trial. *BMC Musculoskeletal Disord* 2007;8:36. doi: 10.1186/1471-2474-8-36.
44. Ibrahim MI, Donatelli RA, Schmitz C, Hellman MA, Buxbaum F. Chronic plantar fasciitis treated with two sessions of radial extracorporeal shock wave therapy. *Foot Ankle Int* 2010;31(5):391-7. doi: 10.3113/fai.2010.0391.
45. Ibrahim MI, Donatelli RA, Hellman M, Hussein AZ, Furia JP, Schmitz C. Long‐term results of radial extracorporeal shock wave treatment for chronic plantar fasciopathy: A prospective, randomized, placebo‐controlled trial with two years follow‐up. *J Ortho Res* 1;35(7):1532-8.
46. Mahindra P, Yamin M, Selhi HS, Singla S, Soni A. Chronic Plantar Fasciitis: Effect of Platelet-Rich Plasma, Corticosteroid, and Placebo. *J Orthopedics* 2016;39(2):e285-9. doi: 10.3928/01477447-20160222-01.
47. Theodore GH, Buch M, Amendola A, Bachmann C, Fleming LL, Zingas C. Extracorporeal shock wave therapy for the treatment of plantar fasciitis. *Foot Ankle Int* 2004;25(5):290-7.
48. Yucel U, Kucuksen S, Cingoz HT, et al. Full-length silicone insoles versus ultrasound-guided corticosteroid injection in the management of plantar fasciitis: a randomized clinical trial. *Prosthet Orthot Int* 2013;37(6):471-6. doi: 10.1177/0309364613478328.
49. Celik D, Kus G, Sirma SO. Joint Mobilization and Stretching Exercise vs Steroid Injection in the Treatment of Plantar Fasciitis: A Randomized Controlled Study. *Foot Ankle Int* 2016;37(2):150-6. doi: 10.1177/1071100715607619.
50. Crawford F, Atkins D, Young P, Edwards J. Steroid injection for heel pain: evidence of short-term effectiveness. A randomized controlled trial. *Rheumatology* 1999;38(10):974-7.
51. Ball EM, McKeeman HM, Patterson C, et al. Steroid injection for inferior heel pain: a randomised controlled trial. *Ann Rheum Dis* 2013;72(6):996-1002. doi: 10.1136/annrheumdis-2012-201508.
52. Hocaoglu S, Vurdem UE, Cebicci MA, et al. Comparative Effectiveness of Radial Extracorporeal Shockwave Therapy and Ultrasound-Guided Local Corticosteroid Injection Treatment for Plantar Fasciitis. *J Am Podiatr Med Assoc* 2017;107(3):192-99. doi: 10.7547/14-114.
53. Eslamian F, Shakouri SK, Jahanjoo F, et al. Extra Corporeal Shock Wave Therapy Versus Local Corticosteroid Injection in the Treatment of Chronic Plantar Fasciitis, a Single Blinded Randomized Clinical Trial. *Pain Med* 2016;17(9):1722-31. doi: 10.1093/pm/pnw113.
54. Kudo P, Dainty K, Clarfield M, Coughlin L, Lavoie P, Lebrun C. Randomized, placebo-controlled, double-blind clinical trial evaluating the treatment of plantar fasciitis with an extracoporeal shockwave therapy (ESWT) device: a North American confirmatory study. *J Ortho Res* 2006;24(2):115-23. doi: 10.1002/jor.20008.
55. Landorf KB, Keenan AM, Herbert RD. Effectiveness of foot orthoses to treat plantar fasciitis: a randomized trial. *Arch Intern Med* 2006;166(12):1305-10. doi: 10.1001/archinte.166.12.1305.
56. Vahdatpour B, Sajadieh S, Bateni V, Karami M, Sajjadieh H. Extracorporeal shock wave therapy in patients with plantar fasciitis. A randomized, placebo-controlled trial with ultrasonographic and subjective outcome assessments. *J Res Med Sci.* 2012;17(9):834-8.
57. Wolgin M, Cook C, Graham C, Mauldin D. Conservative treatment of plantar heel pain: long-term follow-up. *Foot Ankle Int* 1994;15(3):97-102.
58. Hsiao MY, Hung CY, Chang KV, Chien KL, Tu YK, Wang TG. Comparative effectiveness of autologous blood-derived products, shock-wave therapy and corticosteroids for treatment of plantar fasciitis: a network meta-analysis. *Rheumatology* 2015;54(9):1735-43. doi: 10.1093/rheumatology/kev010.
59. Tsikopoulos K, Vasiliadis HS, Mavridis D. Injection therapies for plantar fasciopathy ('plantar fasciitis'): a systematic review and network meta-analysis of 22 randomised controlled trials. *Br J Sports Med* 2016 ;50:1367-1375. doi: 10.1136/bjsports-2015-095437.
60. Almubarak AA, Foster N. Exercise Therapy for Plantar Heel Pain: A Systematic Review. *IJES* 2012;5(3):9.
61. Whittaker GA, Munteanu SE, Menz HB, Tan JM, Rabusin CL, Landorf KB. Foot orthoses for plantar heel pain: a systematic review and meta-analysis. *Br J Sports Med* 2017. doi: 10.1136/bjsports-2016-097355. [published Online First: 2017/09/21].
62. Owen RK, Tincello DG, Keith RA. Network meta-analysis: development of a three-level hierarchical modeling approach incorporating dose-related constraints. *Value in Health* 2015;18(1):116-26.

**Table 1.** Comparative effectiveness results for pain outcome analyses, for each of: A) short term outcomes, B) medium term outcomes, and C) long term outcomes. Summary estimates from the network meta-analysis are shown in lower left triangle, and summary estimates from pairwise meta-analysis (i.e. direct evidence) in upper right triangle. Each cell shows a standardised mean difference (SMD), with a 95% confidence interval in brackets. For any cell, a negative SMD favours the upper-left intervention, and a positive SMD favours the lower-right intervention. Significant results in bold text.

**A**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Placebo** |  | 0.53  (-0.77,1.83) | 0.51  (-0.83,1.86) |  | 0.39  (-1.36,2.13) |  | 0.59  (-0.18,1.35) |
| 0.92  (-0.78,2.62) | **Steroid Inj**  **+Exe** |  |  |  | **-1.20**  **(-2.26,-0.14)** |  |  |
| **0.91 (0.14,1.68)** | -0.01  (-1.73,1.70) | **Steroid Inj** | -0.67  (-2.56,1.22) | **-2.60  (-4.39,-0.81)** | **-1.94  (-3.80,-0.08)** |  | -0.29  (-1.23,0.65) |
| 0.56  (-0.40,1.52) | -0.36  (-2.26,1.55) | -0.35  (-1.40,0.70) | **Orthoses** |  |  | -0.01  (-1.83,1.80) | -0.40  (-2.21,1.42) |
| -1.69  (-3.64,0.26) | **-2.61**  **(-5.09,-0.13)** | **-2.60**  **(-4.39,-0.81)** | **-2.25**  **(-4.33,-0.18)** | **Oral NSAID** |  |  |  |
| -0.28  (-1.62,1.06) | **-1.20**  **(-2.26,-0.14)** | -1.19  (-2.54,0.16) | -0.84  (-2.43,0.74) | 1.41  (-0.83,3.65) | **Exe** |  |  |
| 0.74  (-0.91,2.40) | -0.18  (-2.51,2.16) | -0.16  (-1.87,1.54) | 0.18  (-1.42,1.79) | 2.43  (-0.04,4.90) | 1.03  (-1.06,3.11) | **ESWT +Orthoses** | -0.39  (-2.20,1.43) |
| 0.55  (-0.08,1.19) | -0.37  (-2.12,1.39) | -0.35  (-1.08,0.37) | -0.01  (-1.00,0.99) | **2.24 (0.31,4.17)** | 0.84  (-0.57,2.24) | -0.19  (-1.80,1.42) | **ESWT** |

**B**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Placebo** |  | 0.46  (-1.62,2.55) | 0.30  (-1.75,2.36) |  |  |  |  | 0.54  (-0.67,1.75) |
| -0.10  (-3.58,3.38) | **Steroid Inj**  **+Exe** |  |  |  | -0.99  (-2.70,0.71) |  | -1.17  (-4.09,1.75) |  |
| 0.37  (-0.92,1.66) | 0.47  (-2.77,3.70) | **Steroid Inj** |  | -2.66  (-5.49,0.17) | -1.53  (-4.41,1.34) |  |  | 0.14  (-1.18,1.46) |
| 0.58  (-1.08,2.24) | 0.68  (-3.11,4.47) | 0.21  (-1.77,2.20) | **Orthoses** |  |  | 0.43  (-2.48,3.33) |  | -0.67  (-3.57,2.24) |
| -2.29  (-5.40,0.82) | -2.19  (-6.49,2.11) | -2.66  (-5.49,0.17) | -2.87  (-6.33,0.59) | **Oral NSAID** |  |  |  |  |
| -1.16  (-4.29,1.98) | -1.06  (-2.58,0.46) | -1.53  (-4.39,1.33) | -1.74  (-5.22,1.74) | 1.13  (-2.89,5.16) | **Exe** |  | 0.29  (-2.67,3.25) |  |
| 1.29  (-1.37,3.95) | 1.39  (-2.88,5.65) | 0.92  (-1.87,3.71) | 0.71  (-1.89,3.30) | 3.58  (-0.40,7.55) | 2.45  (-1.55,6.44) | **ESWT**  **+Orthoses** |  | -1.10  (-4.00,1.81) |
| -1.07  (-4.86,2.72) | -0.97  (-3.11,1.17) | -1.44  (-5.01,2.14) | -1.65  (-5.74,2.43) | 1.22  (-3.34,5.78) | 0.09  (-2.06,2.24) | -2.36  (-6.89,2.17) | **ESWT**  **+Exe** |  |
| 0.47  (-0.53,1.47) | 0.57  (-2.85,3.99) | 0.10  (-1.01,1.22) | -0.11  (-1.87,1.65) | 2.76  (-0.28,5.80) | 1.63  (-1.44,4.70) | -0.82  (-3.41,1.78) | 1.54  (-2.20,5.28) | **ESWT** |

**C**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Placebo** |  |  | 0.06  (-1.55,1.67) |  |  |  | **1.22**  **(0.36,2.08)** |
| 1.75  (-1.68,5.19) | **Steroid Inj +Exe** |  |  | 0.10  (-1.55,1.75) |  | 0.00  (-1.61,1.61) |  |
| 1.43  (-0.46,3.32) | -0.32  (-3.20,2.55) | **Steroid Inj** |  |  | 0.18  (-1.51,1.88) |  | -0.22  (-1.91,1.48) |
| 0.06  (-1.55,1.67) | -1.69  (-5.49,2.10) | -1.37  (-3.86,1.12) | **Orthoses** |  |  |  |  |
| 1.86  (-1.95,5.66) | 0.10  (-1.54,1.75) | 0.43  (-2.89,3.74) | 1.80  (-2.34,5.93) | **NSAID Inj +Exe** |  |  |  |
| 1.61  (-0.92,4.14) | -0.14  (-2.47,2.19) | 0.18  (-1.51,1.87) | 1.55  (-1.45,4.55) | -0.25  (-3.10,2.61) | **Exe** | 0.15  (-1.54,1.84) |  |
| 1.75  (-1.29,4.79) | 0.00  (-1.61,1.61) | 0.32  (-2.06,2.71) | 1.69 (-1.75,5.13) | -0.10  (-2.40,2.20) | 0.14  (-1.54,1.83) | **ESWT +Exe** |  |
| **1.22 (0.36,2.07)** | -0.53  (-3.86,2.80) | -0.21  (-1.90,1.48) | 1.16 (-0.67,2.98) | -0.64  (-4.35,3.08) | -0.39  (-2.78,2.00) | -0.54  (-3.45,2.38) | **ESWT** |

Treatment abbreviations: ESWT=Extracorporeal shockwave therapy, ESWT+Exe= Extracorporeal shockwave therapy combined with exercise, ESWT+Orthoses= Extracorporeal shockwave therapy combined with orthoses, Exe=exercise, NSAID Inj+Exe=oral nonsteroidal anti-inflammatory drug combined with exercise, Oral NSAID=oral nonsteroidal anti-inflammatory drug, Orthoses=prefabricated or customised foot orthoses, Placebo=usual care/placebo, Steroid Inj=corticosteroid injection, and Steroid Inj+Exe=corticosteroid injection combined with exercise.

**Table 2.** Network meta-analysis treatment ranking results for pain outcome analyses, for each of: short term outcomes, medium term outcomes, and long term outcomes. Surface under cumulative ranking curve (SUCRA) values (0-100) and mean ranks are presented, based on a simulation with 1000 replications. Note: higher SUCRAs and lower mean ranks indicate better performing treatments.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Short**  **Term Pain** | |  | **Medium**  **Term Pain** | |  | **Long**  **Term Pain** | |
| **Treatment** | **SUCRA** | **Mean Rank** |  | **SUCRA** | **Mean Rank** |  | **SUCRA** | **Mean Rank** |
| **ESWT** | 60.7 | 3.8 |  | 67.2 | 3.6 |  | 54.5 | 4.2 |
|  |  |  |  |  |  |  |  |  |
| **ESWT+Exe** |  |  |  | 29.4 | 6.6 |  | 64.2 | 3.5 |
|  |  |  |  |  |  |  |  |  |
| **ESWT+Orthoses** | 66.5 | 3.3 |  | 80.3 | 2.6 |  |  |  |
|  |  |  |  |  |  |  |  |  |
| **Exe** | 24.6 | 6.3 |  | 26.1 | 6.9 |  | 61.4 | 3.7 |
|  |  |  |  |  |  |  |  |  |
| **NSAID Inj+Exe** |  |  |  |  |  |  | 63.3 | 3.6 |
|  |  |  |  |  |  |  |  |  |
| **Oral NSAID** | 3.7 | 7.7 |  | 13.3 | 7.9 |  |  |  |
|  |  |  |  |  |  |  |  |  |
| **Orthoses** | 60.5 | 3.8 |  | 66.6 | 3.7 |  | 20.0 | 6.6 |
|  |  |  |  |  |  |  |  |  |
| **Placebo** | 30.1 | 5.9 |  | 48.7 | 5.1 |  | 15.6 | 6.9 |
|  |  |  |  |  |  |  |  |  |
| **Steroid Inj** | 79.5 | 2.4 |  | 63.7 | 3.9 |  | 58.4 | 3.9 |
|  |  |  |  |  |  |  |  |  |
| **Steroid Inj+Exe** | 74.4 | 2.8 |  | 54.7 | 4.6 |  | 62.7 | 3.6 |

Treatment abbreviations: ESWT=Extracorporeal shockwave therapy, ESWT+Exe= Extracorporeal shockwave therapy combined with exercise, ESWT+Orthoses= Extracorporeal shockwave therapy combined with orthoses, Exe=exercise, NSAID Inj+Exe=oral nonsteroidal anti-inflammatory drug combined with exercise, Oral NSAID=oral nonsteroidal anti-inflammatory drug, Orthoses=prefabricated or customised foot orthoses, Placebo=usual care/placebo, Steroid Inj=corticosteroid injection, and Steroid Inj+Exe=corticosteroid injection combined with exercise.

**Table 3.** Comparative effectiveness results for function outcome analyses, for each of: A) short term outcomes, B) medium term outcomes, and C) long term outcomes. Summary estimates from the network meta-analysis are shown in lower left triangle, and summary estimates from pairwise meta-analysis (i.e. direct evidence) in upper right triangle. Each cell shows a standardised mean difference (SMD), with a 95% confidence interval in brackets. For any cell, a negative SMD favours the upper-left intervention, and a positive SMD favours the lower-right intervention. Significant results in bold text.

**A**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Placebo** |  |  | 0.30  (-2.98,3.58) | 0.24  (-3.01,3.49) | **1.86**  **(0.19,3.52)** |
| 1.83  (-1.15,4.80) | **Steroid Inj +Exe** |  |  | -1.24  (-3.04,0.56) |  |
| **1.98 (0.10,3.87)** | 0.16  (-2.83,3.14) | **Steroid Inj** | -1.34  (-4.66,1.97) | -1.03  (-4.32,2.26) | -0.46  (-2.34,1.43) |
| 0.47  (-1.91,2.85) | -1.36  (-4.93,2.22) | -1.52  (-3.91,0.88) | **Orthoses** |  |  |
| 0.59  (-1.78,2.96) | -1.24  (-3.03,0.56) | -1.40  (-3.78,0.99) | 0.12  (-2.97,3.21) | **Exe** |  |
| **1.71 (0.26,3.15)** | -0.12  (-3.18,2.95) | -0.28  (-1.87,1.31) | 1.24  (-1.25,3.73) | 1.12  (-1.36,3.61) | **ESWT** |

**B**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Placebo** |  |  | 0.27  (-1.32,1.86) |  | 0.93  (-0.68,2.53) |
| 1.14  (-2.22,4.51) | **Steroid Inj +Exe** |  |  | -1.15  (-2.48,0.18) |  |
| 0.87  (-1.20,2.94) | -0.27  (-2.93,2.39) | **Steroid Inj** |  | -0.88  (-3.18,1.43) | 0.05  (-1.27,1.37) |
| 0.27  (-1.32,1.86) | -0.87  (-4.59,2.85) | -0.60  (-3.22,2.01) | **Orthoses** |  |  |
| -0.01  (-3.09,3.08) | -1.15  (-2.48,0.18) | -0.88  (-3.18,1.42) | -0.28  (-3.75,3.20) | **Exe** |  |
| 0.92  (-0.68,2.53) | -0.22  (-3.18,2.74) | 0.05  (-1.27,1.36) | 0.65  (-1.61,2.91) | 0.93  (-1.72,3.58) | **ESWT** |

**C**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Placebo** |  | 0.11  (-0.26,0.47) |  | **0.95**  **(0.50,1.40)** |
| **0.93**  **(0.23,1.63)** | **Steroid Inj** |  | 0.16  (-0.47,0.79) | 0.02  (-0.51,0.56) |
| 0.11  (-0.26,0.47) | **-0.82**  **(-1.61,-0.03)** | **Orthoses** |  |  |
| **1.09**  **(0.15,2.03)** | 0.16  (-0.47,0.79) | 0.98  (-0.03,1.99) | **Exe** |  |
| **0.95**  **(0.50,1.40)** | 0.03  (-0.51,0.56) | **0.84**  **(0.26,1.43)** | -0.14  (-0.96,0.69) | **ESWT** |

Treatment abbreviations: ESWT=Extracorporeal shockwave therapy, Exe=exercise, Orthoses=prefabricated or customised foot orthoses, Placebo=usual care/placebo, Steroid Inj=corticosteroid injection, and Steroid Inj+Exe=corticosteroid injection combined with exercise.

**Table 4.** Network meta-analysis treatment ranking results for function outcome analyses, for each of: short term outcomes, medium term outcomes, and long term outcomes. Surface under cumulative ranking curve (SUCRA) values (0-100) and mean ranks are presented, based on a simulation with 1000 replications. Note: higher SUCRAs and lower mean ranks indicate better performing treatments.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Short**  **Term Function** | |  | **Medium**  **Term Function** | |  | **Long**  **Term Function** | |
| **Treatment** | **SUCRA** | **Mean Rank** |  | **SUCRA** | **Mean Rank** |  | **SUCRA** | **Mean Rank** |
| **ESWT** | 69.5 | 2.5 |  | 65.6 | 2.7 |  | 72.8 | 2.1 |
|  |  |  |  |  |  |  |  |  |
| **Exe** | 32.2 | 4.4 |  | 29.9 | 4.5 |  | 82.1 | 1.7 |
|  |  |  |  |  |  |  |  |  |
| **Orthoses** | 31.8 | 4.4 |  | 42.4 | 3.9 |  | 19.4 | 4.2 |
|  |  |  |  |  |  |  |  |  |
| **Placebo** | 16.9 | 5.2 |  | 28.1 | 4.6 |  | 7.3 | 4.7 |
|  |  |  |  |  |  |  |  |  |
| **Steroid Inj** | 78.9 | 2.1 |  | 62.7 | 2.9 |  | 68.4 | 2.3 |
|  |  |  |  |  |  |  |  |  |
| **Steroid Inj +Exe** | 70.6 | 2.5 |  | 71.4 | 2.4 |  |  |  |

Treatment abbreviations: ESWT=Extracorporeal shockwave therapy, Exe=exercise, Orthoses=prefabricated or customised foot orthoses, Placebo=usual care/placebo, Steroid Inj=corticosteroid injection, and Steroid Inj+Exe=corticosteroid injection combined with exercise.